Capital Asset Advisory Services LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ – Get a rating) by 6.1% during the 1st quarter, according to the company in its most recent Form 13F filed with the Securities and Exchange Commission. The fund held 16,338 shares of the company after buying an additional 939 shares during the period. Capital Asset Advisory Services LLC’s holdings in Johnson & Johnson were worth $2,896,000 when it last filed with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently changed their positions in the company. Riversedge Advisors LLC increased its holdings in Johnson & Johnson by 8.6% in the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company valued at $627,000 after acquiring 289 additional shares in the last quarter. Hancock Whitney Corp increased its holdings in Johnson & Johnson by 0.3% in the fourth quarter. Hancock Whitney Corp now owns 65,612 shares of the company valued at $11,224,000 after acquiring 211 additional shares in the last quarter. PRW Wealth Management LLC increased its holdings in Johnson & Johnson by 13.7% in the fourth quarter. PRW Wealth Management LLC now owns 2,385 shares of the company valued at $408,000 after acquiring 287 additional shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. increased its stake in Johnson & Johnson by 7.2% in the fourth quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 8,926 shares of the company valued at $1,527,000 after acquiring 599 additional shares in the last quarter. Finally, Hamlin Capital Management LLC increased its stake in Johnson & Johnson by 3.5% in the fourth quarter. Hamlin Capital Management LLC now owns 518,653 shares of the company valued at $88,726,000 after acquiring an additional 17,489 shares in the last quarter. 68.78% of the shares are currently held by institutional investors.
Insider Activity at Johnson & Johnson
In other news, CAD Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, which is available via this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following completion of the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via this link. Also, VPE Kathryn E. Wengel sold 40,000 Johnson & Johnson shares in a trade on Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. Disclosure of this sale can be found here. 0.35% of the shares are currently held by insiders.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $172.12 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt ratio of 0.39. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock’s 50-day moving average is $176.25 and its 200-day moving average is $174.36. The company has a market capitalization of $452.92 billion, a price/earnings ratio of 25.05, a PEG ratio of 3.48 and a beta of 0.63.
Johnson & Johnson (NYSE:JNJ – Get a rating) last released its quarterly results on Tuesday, July 19. The company reported earnings per share of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company’s quarterly revenue increased 3.0% from the same quarter last year. In the same quarter of the previous year, the company achieved EPS of $2.48. Sell-side analysts expect Johnson & Johnson to post EPS of 10.05 for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio is 65.79%.
Changes to analyst ratings
Several brokerages have recently commented on JNJ. SVB Leerink slashed its target price on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday. Raymond James raised his price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a Wednesday, April 20 research note. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research note. Goldman Sachs Group raised its price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a Tuesday, April 12 research note. Finally, Citigroup lowered its price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday. Four analysts gave the stock a hold rating, six gave the stock a buy rating and one gave the stock a strong buy rating. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $189.89.
Johnson & Johnson profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.